Table 2.
Adherence to ACE checklist
Section | topic | Total (%) (n = 108) |
JCR Q1(%) (n = 71) |
Others (%) (n = 37) |
P value |
---|---|---|---|---|---|
Title and abstract | 1 Title and abstract | 70(64.8) | 50(70.4) | 20(54.1) | 0.14 |
Introduction | 2 Background and objectives | 95(88.0) | 63(88.7) | 32(86.5) | 0.98 |
Methods | 3 Trial design | 92(85.2) | 63(88.7) | 29(78.4) | 0.25 |
4 Participants | 78(72.2) | 49(69.0) | 29(78.4) | 0.42 | |
5 Interventions | 88(81.5) | 58(81.7) | 30(81.1) | 1.00 | |
6 Outcomes | 72(66.7) | 49(69.0) | 23(62.2) | 0.62 | |
7 Sample size and operating characteristics | 59(54.6) | 40(56.3) | 19(51.4) | 0.77 | |
Randomization | 8 Sequence generation | 29(26.9) | 18(25.4) | 11(29.7) | 0.80 |
9 Allocation concealment mechanism | 34(31.5) | 25(35.2) | 9(24.3) | 0.35 | |
10 Implementation | 24(22.2) | 17(23.9) | 7(18.9) | 0.72 | |
11 Blinding | 12(11.1) | 8(11.3) | 4(10.8) | 1.00 | |
12 Statistical methods | 59(54.6) | 40(56.3) | 19(51.4) | 0.77 | |
Results | 13 Participant flow | 37(34.3) | 22(31.0) | 15(40.5) | 0.44 |
14 Recruitment and adaptations | 65(60.2) | 37(52.1) | 28(75.7) | 0.03 | |
15 Baseline data | 25(23.1) | 10(14.1) | 15(40.5) | < 0.01 | |
16 Numbers analysed | 100(92.6) | 66(93.0) | 34(91.9) | 1.00 | |
17 Outcomes and estimation | 23(21.3) | 12(16.9) | 11(29.7) | 0.19 | |
18 Ancillary analyses | 94(87.0) | 63(88.7) | 31(83.8) | 0.67 | |
19 Harms | 103(95.4) | 67(94.4) | 36(97.3) | 0.84 | |
Discussion | 20 Limitations | 34(31.5) | 20(28.2) | 14(37.8) | 0.42 |
21 Generalisability | 17(15.7) | 11(15.5) | 6(16.2) | 1.00 | |
22 Interpretation | 107(99.1) | 70(98.6) | 37(100) | 1.00a | |
Other information | 23 Registration | 65(60.2) | 43(60.6) | 22(59.5) | 1.00 |
24a Protocol | 23(21.3) | 18(25.4) | 5(13.5) | 0.24 | |
24b SAP and other relevant documents | 8(7.4) | 6(8.5) | 2(5.4) | 0.85 | |
25 Funding | 92(85.2) | 61(85.9) | 31(83.8) | 0.99 |
Values in parentheses are percentages unless indicated otherwise
aFisher’s exact test